Literature DB >> 24778028

MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype.

Stefan Steurer1, Ahmad Shoaib Seddiqi, Julius Magnus Singer, Ahmad Soliaman Bahar, Christian Eichelberg, Michael Rink, Roland Dahlem, Hartwig Huland, Guido Sauter, Ronald Simon, Sarah Minner, Eike Burandt, Phillip R Stahl, Thorsten Schlomm, Marcus Wurlitzer, Hartmut Schlüter.   

Abstract

AIM: To identify molecular features associated with clinico-pathological parameters in renal cell cancer.
MATERIALS AND METHODS: Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging was employed for a kidney cancer tissue microarray containing tissue samples from 789 patients for which clinical follow-up data were available.
RESULTS: A comparison of mass spectrometric signals with clinico-pathological features revealed significant differences between papillary and clear cell renal cell cancer. Within the subgroup of clear cell RCC, statistical associations with tumor stage (seven signals, p<0.01 each), Fuhrman grade (seven signals, p<0.0001 each), and presence of lymph node metastases (10 signals, p<0.01 each) were found. In addition, the presence of one signal was significantly linked to shortened patient survival (p=0.0198).
CONCLUSION: Our data pinpoint towards various molecules with potential relevance in renal cell cancer. They also demonstrate that the combination of the MALDI mass spectrometry imaging and large-scale tissue microarray platforms represents a powerful approach to identify clinically-relevant molecular cancer features.

Entities:  

Keywords:  MALDI mass spectrometry imaging; MALDI-MSI; biomarker; renal cell cancer; tissue microarray

Mesh:

Year:  2014        PMID: 24778028

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice.

Authors:  Michaela Aichler; Axel Walch
Journal:  Lab Invest       Date:  2015-01-26       Impact factor: 5.662

2.  MALDI-Mass Spectrometric Imaging Revealing Hypoxia-Driven Lipids and Proteins in a Breast Tumor Model.

Authors:  Lu Jiang; Kamila Chughtai; Samuel O Purvine; Zaver M Bhujwalla; Venu Raman; Ljiljana Paša-Tolić; Ron M A Heeren; Kristine Glunde
Journal:  Anal Chem       Date:  2015-06-04       Impact factor: 6.986

3.  Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes.

Authors:  Franziska Erlmeier; Annette Feuchtinger; Daniela Borgmann; Martina Rudelius; Michael Autenrieth; Axel Karl Walch; Gregor Weirich
Journal:  Histochem Cell Biol       Date:  2015-05-01       Impact factor: 4.304

4.  MicroLESA: Integrating Autofluorescence Microscopy, In Situ Micro-Digestions, and Liquid Extraction Surface Analysis for High Spatial Resolution Targeted Proteomic Studies.

Authors:  Daniel J Ryan; Nathan Heath Patterson; Nicole E Putnam; Aimee D Wilde; Andy Weiss; William J Perry; James E Cassat; Eric P Skaar; Richard M Caprioli; Jeffrey M Spraggins
Journal:  Anal Chem       Date:  2019-05-31       Impact factor: 6.986

5.  βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma.

Authors:  Alexander Quaas; Amir-Hossein Rahvar; Christoph Burdelski; Christina Koop; Christian Eichelberg; Michael Rink; Roland Dahlem; Thorsten Schlomm; Maria Christina Tsourlakis; Ronald Simon; Sarah Minner; Guido Sauter; Stefan Steurer
Journal:  World J Urol       Date:  2014-12-21       Impact factor: 4.226

6.  Identification of Protein Markers Specific for Papillary Renal Cell Carcinoma Using Imaging Mass Spectrometry.

Authors:  Chan Hyun Na; Ji Hye Hong; Wan Sup Kim; Selina Rahman Shanta; Joo Yong Bang; Dongmin Park; Hark Kyun Kim; Kwang Pyo Kim
Journal:  Mol Cells       Date:  2015-06-10       Impact factor: 5.034

7.  Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma.

Authors:  Juan Yang; Jin Yang; Yan Gao; Lingyu Zhao; Liying Liu; Yannan Qin; Xiaofei Wang; Tusheng Song; Chen Huang
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

8.  MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas.

Authors:  Franziska Erlmeier; Na Sun; Jian Shen; Annette Feuchtinger; Achim Buck; Verena M Prade; Thomas Kunzke; Peter Schraml; Holger Moch; Michael Autenrieth; Wilko Weichert; Arndt Hartmann; Axel Walch
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.639

9.  Metabolomics profiling of methamphetamine addicted human serum and three rat brain areas.

Authors:  Ming Lin; Jiamin Xu; Xi Liu; Zhenfeng Dai; Zhimin Liu; Xin Zhao; Yi Sun; Xiaoping Pu
Journal:  RSC Adv       Date:  2019-12-12       Impact factor: 4.036

10.  In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on 99mTc-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination.

Authors:  Thomas Papathomas; Antonios Tzortzakakis; Na Sun; Franziska Erlmeier; Annette Feuchtinger; Kiril Trpkov; Alina Bazarova; Alexandros Arvanitis; Wanzhong Wang; Bela Bozoky; Georgia Kokaraki; Rimma Axelsson; Axel Walch
Journal:  Eur Urol Open Sci       Date:  2020-11-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.